All companies
Visit website
AJNA BIOSCIENCES
OperatingAJNA BioSciences PBC
Healthcare · Biotech
Transforming the $678B pharmaceutical industry with plant medicine
Post-money valuation ⓘ
$126.1M
As of Oct 2025 · from Reg CF Offering (2025) · pre-money + amount raised, not a traded price
Total raised
$2,274,362
Across 2 rounds since 2024
Latest share price
$4.83
Reg CF Offering (2025) offering price
Financials
FY2022–FY2025 · from SEC filings · hover any figure for its source$415K
−$4.1M
2022
$4.6M
$9.4M
2023
$3.3M
−$2.4M
2024
$1.7M
−$3.8M
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2022
FY2023
FY2024
FY2025
Income statement
Revenue
$415,364
$4,558,657
$3,267,479
$1,692,791
Cost of goods sold
$415,364
$4,558,657
$3,267,479
$1,692,791
Gross margin
0%
0%
0%
0%
Net income
-$4,066,700
$9,372,650
-$2,359,584
-$3,800,746
Taxes paid
$0
$30,000
$30,000
$0
Balance sheet
Cash
$532,128
$984,298
$1,927,679
$368,452
Accounts receivable
$415,364
$0
$0
$0
Total assets
$3,003,351
$13,306,444
$16,627,450
$13,800,386
Short-term debt
$1,176,130
$9,619,653
$512,725
$1,496,442
Long-term debt
$8,180,430
$715,011
$1,953,013
$385,819
Total liabilities
$9,356,560
$10,334,664
$2,465,738
$1,882,261
Other
Headcount
—
16
20
16
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$41.2M
post-money
$126.1M
post-money
AJNA BIOSCIENCES Preferred Stock 1
Reg CF Offering (2025)
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $1M / $1.5MInvestors 346Post-money $126.1M
Raised $1.2M / $1.2MInvestors 552Post-money $41.2M
Reg CF annual-report compliance
Compliant
Filed 2 of 2 annual reports (FY2024–FY2025)
552 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 11 filings on EDGARSource: ManualCIK 0001900590Share price $4.83
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.